



## LETTER TO THE EDITOR

### Thiopental as substitute therapy for critically ill patients with COVID-19 requiring mechanical ventilation and prolonged sedation



### El uso de tiopental como alternativa para pacientes críticos con COVID-19 que requieren ventilación mecánica y sedación prolongada

Dear Editor,

Critically ill patients with COVID-19 require high sedative drugs doses under invasive mechanical ventilation (MV).<sup>1</sup> Moreover, most of them need long MV periods because of prolonged course of respiratory failure.<sup>2</sup> The Food and Drug Administration recently issued a midazolam shortage and reported a more than 50% consumption increase for other common sedative drugs such as propofol due to high demand for patients with COVID-19.<sup>3</sup>

Thiopental is commonly used in refractory status epilepticus as burst suppression therapy or in traumatic brain injury to limit increase in cranial pressure.<sup>4,5</sup> For these patients, barbiturate therapy induce deep coma with bispectral index score lower than 20 and, as a result, prolonged MV.<sup>4</sup> To our knowledge, no study has reported use of thiopental in critically ill patients besides acute neurological conditions.

We retrospectively analyzed our experience with thiopental in our intensive care unit (ICU) patients with COVID-19 pneumonia during a shortage of midazolam and propofol. Twenty-two patients with COVID-19 pneumonia required MV between March 15 and April 15, 2020. During their ICU stay, 2 patients were transferred to an extra corporeal membrane oxygenation referral center for worsening respiratory failure. Of the remaining 20 patients, 7 have received thiopental as a result of major agitation and/or patient-ventilator asynchrony recurrence despite delivery of usual recommended doses of sedatives and analgesics. For all studied patients, baseline data on ICU admission and sedatives treatment during ICU stay are reported in Table 1. Data were analyzed with the chi-squared test or Fischer exact test for categorical parameters and Mann–Whitney test for continuous variables. Most patients ( $n=20$ ) have received a combination of midazolam, propofol and sufentanil. In the thiopental group, patients have received more midazolam, opioids and have required a longer duration of neuromuscular blockade agents (NMBA). Time to extubation after sedation cessation, duration of MV and outcome were not different between the two

groups. Sedation, analgesia and barbiturates management for each patient of the thiopental group are reported in Table 2. Thiopental was delivered  $10.3 \pm 3.9$  days after ICU admission. A bolus infusion of thiopental at a dose of 3 mg/kg was administered before starting continuous infusion. Bispectral index (BIS) monitoring was used to determine adequate thiopental dosage. A BIS level between 40 and 60 and the discontinuation of patient-ventilator asynchrony were the goal to be achieved. Highest mean dose of thiopental was  $3.4 \pm 0.8$  mg/kg/h. There was no more patient-ventilator asynchrony. Thiopental was progressively reduced by half every 12 h according to clinical status and was delivered overall during  $4.8 \pm 1.8$  days. Just before thiopental initiation, mean doses of midazolam and propofol were respectively  $16 \pm 7.6$  and  $120 \pm 76.6$  mg/h. Midazolam and propofol were completely stopped one hour after the thiopental loading dose in all patients. Only one patient needed initiation of small doses of norepinephrine. Cisatracurium could be stopped  $1.3 \pm 1.2$  days following thiopental initiation. Mean level of bispectral index monitoring during thiopental infusion was between 40 and 50. Dexmedetomidine, commonly used in our unit during sedative drugs withdrawal, was administered to 6 patients. A Richmond Agitation Sedation Scale (RASS) score at 0 was obtained  $3.8 \pm 1.1$  days following thiopental cessation. Five of seven patients survived the ICU stay. All surviving patients were discharged from the ICU with a Glasgow score  $\geq 14$ .<sup>5</sup>

More severely ill patients with COVID-19 require deep sedation with combination of multiple agents during 2–3 weeks. The recommended drug strategy to maintain a RASS score of  $-4$  or  $-5$  is the combination of midazolam with an opiate and propofol.<sup>6</sup> However, prolonged and high requirements of sedatives and opioids can lead to drug tolerance, accumulation, withdrawal and/or propofol syndrome. Government agencies and medical organizations have reported major shortage of benzodiazepines and propofol during the COVID-19 pandemic and providing sedation with less commonly used agents as barbiturates has been suggested.<sup>1</sup> Major side effects of thiopental are essentially hypotension and prolonged ICU stay. In our unit, we have used thiopental in patients presenting with severe ventilator asynchrony despite delivery of usual recommended doses of sedatives, opioids and NMBA.<sup>7</sup> Low dose of vasopressor was started in only one patient and norepinephrine was decreased in three patients 24 h following thiopental initiation. BIS monitoring was used to determine adequate dosage of thiopental. Low BIS level ( $<40$ ) has been associated with long term mortality ( $\geq 1$  year).<sup>8</sup> In our study, a level ranged from 40 to 50 prevented deep sedation and large accumulation of barbiturates. Midazolam and propofol could be totally

**Table 1** Baseline data, treatment characteristics and clinical outcome in the two studied groups.

	Patients with thiopental (n = 7)	Patients without thiopental (n = 13)	P
Male sex, n =	6	11	0.99
Age (years), mean ± SD	64.9 ± 10.5	66.5 ± 9.0	0.91
SAPS II score, mean ± SD	41.1 ± 9.2	37.8 ± 13.2	0.3
<i>Sedatives and opioids during ICU stay</i>			
Duration of midazolam (days), mean ± SD	9.3 ± 3.0	10.3 ± 8.4	0.91
Dose of midazolam per patient and per day (mg), mean ± SD	318.9 ± 85.6	207.0 ± 101.5	0.03
Duration of propofol (days), mean ± SD	10.3 ± 3.5	10.5 ± 8.0	0.69
Dose of propofol per patient and per day (mg), mean ± SD	1895 ± 614	1836 ± 896	0.43
Duration of sufentanil (days), mean ± SD	16.7 ± 4.6	13.4 ± 9.3	0.19
Dose of sufentanil per patient and per day (µg), mean ± SD	580.4 ± 165.1	425.5 ± 154.1	0.06
<i>NMBA use during ICU stay, n =</i>			
Duration of NMBA (days), mean ± SD	7	11	
Duration of vasoactive drugs (days), mean ± SD	9.1 ± 2.9	5.2 ± 4.6	0.04
Duration of vasoactive drugs (days), mean ± SD	10.4 ± 3.5	6.5 ± 5.7	0.12
Extubation time (days) mean ± SD <sup>a</sup>	3.0 ± 1.6	3.4 ± 2.4	0.93
Duration of MV (days), mean ± SD	20.4 ± 5.3	16.9 ± 11.7	0.25
Duration of ICU stay, (days), mean ± SD	23.6 ± 6.1	19.9 ± 11.6	0.38
Number of deaths, n =	2	6	0.54

<sup>a</sup> Extubation time is the period between cessation of sedation and extubation and concerned only discharged patients.

Abbreviations: SAPS II: Simplified Acute Physiologic Score; NMBA: neuromuscular blockade agent; ICU: Intensive Care Unit; SD: Standard deviation.

**Table 2** Baseline data and characteristics of sedation, analgesia and NMBA delivery just before and following thiopental initiation.

Patients	1	2	3	4	5	6	7
<i>Demographics</i>							
Male	Yes	Yes	Yes	No	Yes	Yes	Yes
Age in years	55	70	46	72	72	65	74
SAPS II score	38	42	25	48	54	44	37
SOFA score at T0	11	11	7	7	7	11	7
<i>Sedation and vasopressor at T0</i>							
Midazolam (mg/h)	20	12	20	20	0	20	20
Sufentanil (µg/h)	40	20	40	40	20	30	30
Propofol (mg/h)	180	100	200	200	100	60	0
Norepinephrine (mg/h)	1	0.3	0	0	0	0.25	0
<i>Cisatracurium at T0 (mg/h)</i>	20	20	20	0	15	10	20
<i>TOF score (I4) at T0</i>	4	4	4	4	4	4	4
<i>Day of thiopental initiation after ICU admission</i>	16	6	8	15	10	10	7
<i>Sedation and vasopressor at T1</i>							
Thiopental (mg/kg/h)	2.9	4.7	4.2	4	2.3	3.1	2.7
Midazolam (mg/h)	0	0	0	0	0	0	0
Sufentanil (µg/h)	40	20	40	20	10	35	30
Propofol (mg/h)	0	0	0	0	0	0	0
Norepinephrine (mg/h)	0.4	0.4	0	0	0.05	0.15	0
<i>Thiopental duration (days)</i>	5	7	5	6	3	2	6
<i>BIS during thiopental infusion (mean ± SD)</i>	47.6 ± 9	40.4 ± 8.1	47.8 ± 8.1	NA	NA	44.8 ± 2.5	40.2 ± 4.2
<i>Glasgow score at ICU discharge</i>	15	15	15	NR	14	NR	14
<i>Death</i>	No	No	No	Yes	No	Yes	No

T0: Time just before thiopental initiation. T1: Time at 24h following thiopental initiation.

SAPS II: Simplified Acute Physiology Score II; SOFA: Sepsis-related Organ Failure Assessment; TOF: Train-of-four; NR: not relevant; NA: not available.

discontinued allowing a significant sparing of these drugs and extubation time was similar between the two groups. Dexmedetomidine was used in the two groups of patients during withdrawal of sedative drugs to prevent occurrence of delirium as recommended by a recent guideline.<sup>6</sup> Another drug option for sedation of critically ill patients with COVID-19 could be inhaled volatile anaesthetics.<sup>9,10</sup> Some studies have reported that inhaled agents such as isoflurane and sevoflurane shorten awakening and extubation times in mechanically ventilated patients compared to benzodiazepines or propofol. Another benefit of volatile anaesthetics could be pulmonary anti-inflammatory effects and dose-dependent bronchodilatation. However, most of these studies included patients with a mean sedation duration less than 4 days and the potential effects of volatile anaesthetics in mechanically ventilated COVID-19 patients remains to be studied.

Thiopental seems to be an acceptable substitute to sedative drugs in this period of high midazolam and propofol demand for ICU patients with COVID-19. When barbiturate therapy can be discontinued, awakening occurs relatively quickly if bispectral index scores were kept between 40 and 50.

## References

- Hanidziar D, Bittner E. Sedation of mechanically ventilated COVID-19 patients: challenges and special considerations. *Anesth Analg*. 2020, <http://dx.doi.org/10.1213/ANE.0000000000004887>.
- McGrath BA, Brenner MJ, Warrillow SJ, Pandian V, Arora A, Cameron TS, et al. Tracheostomy in the COVID-19 era: global and multidisciplinary guidance. *Lancet Respir Med*. 2020. S2213-2600(20)30230-7.
- Silverman EA. New covid-19 problem: shortages of medicines needed for placing patients on ventilators; 2020. Available from: <https://www.statnews.com/pharmalot/2020/03/31/a-new-covid-19-problem-shortages-of-medicines-needed-for-placing-patients-on-ventilators/> [accessed 1.04.20].
- Ryu JA, Jung W, Jung YJ, Kwon DY, Kang K, Choi H, et al. Early prediction of neurological outcome after barbiturate coma therapy in patients undergoing brain tumor surgery. *PLOS ONE*. 2019;14:e0215280.
- Holtkamp M. Pharmacotherapy for refractory and super-refractory status epilepticus in adults. *Drugs*. 2018;78:307–26.
- Celis-Rodríguez E, Díaz Cortés JC, Cárdenas Bolívar YR, Carrizosa González JA, Pinilla DI, Ferrer Zaccaro LE, et al. Evidence-based clinical practice guidelines for the management

- of sedoanalgesia and delirium in critically ill adult patients. *Med Intensiva*. 2020;44:171–84.
7. Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium immobility, and sleep disruption in adult patients in the ICU. *Crit Care Med*. 2018;46:e825–73.
  8. Zorrilla-Vaca A, Healy RJ, Wu CL, Grant MC. Relation between bispectral index measurements of anesthetic depth and post-operative mortality: a meta-analysis of observational studies. *Can J Anaesth*. 2017;64:597–607.
  9. Nieuwenhuijs-Moeke GJ, Jainandunsing JS, Struys MMRF. Sevoflurane, a sigh of relief in COVID-19? *Br J Anaesth*. 2020. S0007-0912(20)30299-3.
  10. Jerath A, Ferguson ND, Cuthbertson B. Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS. *Int Care Med*. 2020:1–4.

V. Jean-Michel, T. Caulier, P.-Y. Delannoy, A. Meybeck, H. Georges\*

*Intensive Care Unit, Centre Hospitalier de Tourcoing, Tourcoing, France*

\* Corresponding author.

E-mail address: [hgeorges@ch-tourcoing.fr](mailto:hgeorges@ch-tourcoing.fr) (H. Georges).

<https://doi.org/10.1016/j.medin.2020.07.013>

0210-5691/ © 2020 Elsevier España, S.L.U. y SEMICYUC. All rights reserved.

## Use of the video laryngoscopy in intensive care units



## Uso de la videolaringoscopia en las unidades de cuidados intensivos

Dear Editor,

We have carefully read the interesting study by Dey et al.<sup>1</sup> comparing the use of the C-MAC video laryngoscope versus the Macintosh laryngoscope. We congratulate the authors for this. Several appreciations may be of interest.

In the methodological aspect, the absence of registration of the airway characteristics (for example, use of the MACOCHA scale) is a significant bias as the authors indicated since it does not guarantee the comparability of both groups. Moreover, the critically ill patient is characterized by a limited physiologic reserve, so the variable “time” as well as the success rate of each device, has a significant clinical impact.<sup>2</sup> In other words, success is not enough. It must be obtained in the shortest time; otherwise, it may increase morbidity and mortality secondary to hypoxia.<sup>3</sup> It is recommended in clinical practice to reduce the number of attempts to three as well as the instrumentalization time to avoid progression to a “cannot intubate cannot oxygenate” situation and to opt for alternative methods or devices in the event of a failed primary attempt.<sup>4</sup> The authors do not specify the local algorithm followed when failed intubation was declared, which is important. The study determined that the C-MAC required significantly more times a stylet to perform tracheal intubation. It is necessary to remember that there are several case reports of the upper airway injury secondary to its use as an adjuvant.

Currently, the routine use of video laryngoscopy<sup>5</sup> is defended in order to perform atraumatic tracheal intubations in the shortest time, although it is important to take care of two aspects; the experience and the type of device selected according to the context; otherwise, the results may differ from those expected.<sup>5</sup> Thus, video laryngoscopes with Macintosh blade such as C-MAC (Karl Storz, Tuttlingen, Germany) or McGrath MAC (Aircraft Medical,

Edinburgh, United Kingdom) allow both direct and indirect laryngoscopy, making them the most appropriate for routine use, while those with a hyperangulated blade with or without a guide channel are reserved to treat the difficult airway as first choice or as a rescue device.<sup>5</sup> There are many reasons that justify the use of a video laryngoscope as a primary device<sup>5</sup>; they allow direct and indirect laryngoscopy in the case of those who have a Macintosh blade as previously exposed, reduce the incidence of an unanticipated difficult airway, optimize training by allowing instructions from a more experienced operator, maximize coordination of the team, allow the recording of the procedure, reduce the possibility of cross-infection when using disposable material and allow a greater distance from the operator with the airway of the patient.<sup>6</sup>

There are limited number of clinical trials on video laryngoscopy in critically ill patients. Similar multicenter studies are necessary to obtain more evidence in this setting.

## Conflicts of interest

The authors declare no conflicts of interests.

## References

1. Dey S, Pradhan D, Saikia P, Bhattacharyya P, Khandelwal H, Adarsha KN. Intubation in the Intensive Care Unit: C-MAC video laryngoscope versus Macintosh laryngoscope. *Med Intensiva*. 2020;44:135–41.
2. Cook TM. Strategies for the prevention of airway complications – a narrative review. *Anaesthesia*. 2018;73:93–111.
3. Yeatts DJ, Dutton RP, Hu PF, Chang YW, Brown CH, Chen H, et al. Effect of video laryngoscopy on trauma patient survival: a randomized controlled trial. *J Trauma Acute Care Surg*. 2013;75:212–9.
4. Higgs A, McGrath BA, Goddard C, Rangasami J, Suntharalingam G, Gale R, et al. Guidelines for the management of tracheal intubation in critically ill adults. *Br J Anaesth*. 2018;120:323–52.
5. Gómez-Ríos MA, Sastre-Rincon JA, Mariscal-Flores M. Is direct laryngoscopy dead? Long live the video laryngoscopy. *Rev Esp Anestesiol Reanim*. 2019;66:177–80.